Moleculin Biotech Business Summary

Moleculin Biotech, Inc. (MBRX) is a clinical-stage pharmaceutical company that operates on a pre-revenue business model, primarily generating capital through equity offerings, warrant exercises, and non-dilutive research grants to fund its drug development pipeline. The company’s primary business segments are focused on oncology and infectious diseases, leveraging three core technology platforms: Annamycin, a next-generation anthracycline; the WP1066 portfolio of immune/transcription modulators; and the WP1122 portfolio of antimetabolites. As of February 2026, the company is advancing its lead candidate, Annamycin, through the pivotal Phase 2B/3 MIRACLE trial for relapsed or refractory acute myeloid leukemia (AML). Moleculin competes directly with other oncology-focused biotechs such as OnKure Therapeutics, SCYNEXIS, and Quince Therapeutics, positioning itself as a niche player specializing in overcoming multidrug resistance and eliminating the cardiotoxicity typically associated with traditional chemotherapy. The leadership team is headed by Co-founder, Chairman, and CEO Walter "Wally" Klemp, a serial entrepreneur who previously co-founded Soliton, Inc. (acquired by AbbVie) and Drypers Corporation. Key executives include Executive Vice President and CFO Jonathan P. Foster, who brings over 30 years of financial experience and previously served on the board of Soliton, and Senior Chief Medical Officer Dr. John Paul Waymack. The scientific direction is led by Chief Scientific Officer Dr. Donald Picker, who is notable for his role in the development of the blockbuster cancer drugs carboplatin and cisplatin. The company’s board of directors features high-pedigree industry veterans such as Dr. Joy Yan, a former CMO at Ambrx, and Michael D. Cannon, former CSO of SICOR (acquired by Teva). Notable institutional support has historically included positions from Armistice Capital, Jane Street Group, and Geode Capital Management.